Global X China Robotics And Ai ETF (02807.HK) Falls 3.74% in Afternoon Trade, Turnover at HKD 6.3229 Million
NewTimeSpace News: As of 14:13 on June 26, Global X China Robotics And Ai ETF (02807.HK) decreased 3.74%, trading at HKD 62.360, with a high of HKD 65.500 and a low of HKD 62.080, representing an intraday amplitude of 5.28%. The ETF recorded a volume of 99,900 shares with a turnover of HKD 6.3229 Million, at an average price of HKD 63.305. The Assets Under Management (AUM) is approximately HKD 1.042 Billion, with the latest Net Asset Value (NAV) at HKD 64.944 and a premium of -0.25%.
Global X China Robotics And Ai Etf (02807.HK) tracks the China Robotics and AI Thematic Index, which covers listed companies in industrial robotics, service robotics, and AI applications in the A-share and Hong Kong markets, reflecting the development trends of China's smart manufacturing and AI industries.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- Global X China Robotics And Ai Etf (02807.HK) Rises 3.16% Intraday, Turnover at HKD 5.8305 Million
- Global X China Robotics And Ai Etf (02807.HK) Drops 2.15% Intraday, AUM at Approximately HKD 991 Million
- Global X China Robotics And Ai Etf (02807.HK) Fell 3.32% Intraday, with the AUM of approximately HKD 1.051 billion
- Global X China Robotics And Ai Etf (02807.HK) extended its gain to 2.46%, as humanoid robots are poised to become a key embodiment of embodied intelligence.
- Global X China Robotics And Ai Etf(02807.HK) surged over 2% in late trading! Institutions: AI applications are expected to emerge and accelerate commercialization